Albany Molecular Research Inc. signed a letter of intent with Bristol-Myers Squibb Co. to replace and consolidate Albany’s Molecular’s original agreement with DuPont Pharmaceuticals Co., in addition to signing a new agreement giving BMS access to AMRI’s natural products library. (BioWorld Today) Read More
